Young men who have sex with men (YMSM) said the treatment’s efficacy was the most important feature injectable HIV pre-exposure prophylaxis (PrEP), over side effects, cost, protection duration, and ...

In a large clinical trial assessing Apretude, ViiV Healthcare’s recently approved injectable drug, as a form of HIV prevention, seven participants contracted the virus despite receiving their ...

Share on Pinterest Research finds a new injectable form of PrEP is superior to daily oral tablets to prevent the contraction of HIV. Sara Jurado/Getty Images New research sheds light on the efficacy ...

The burden of taking a daily dose of PrEP might soon be lifted. According to updated CDC guidelines, bi-monthly injectable PrEP is expected to receive FDA approval by February. The injectable ...

Uganda has received its first consignment of Lenacapavir, a long-acting HIV prevention injection administered twice a year, ...

Long-acting CAB+RPV is preferred by patients for ART due to reduced dosing frequency and stigma, with 89% switching after viral suppression. Studies like PILLAR and EBONI confirm the effectiveness and ...

Add Yahoo as a preferred source to see more of our stories on Google. Ian L. Haddock founder of the normal anomaly I was born in Galveston County, Texas, the very place where, on June 19, 1865, ...

ViiV expects injectables to steal significant market share from oral treatments, such as Gilead’s Biktarvy, which currently dominate the HIV field. In the prevention arena, the company is awaiting an ...

A recent study has found that lenacapavir, an injectable medication administered twice a year, is more effective at preventing HIV among gay, bisexual, and transgender people than a daily regimen of ...

The federal Food and Drug Administration has approved Apretude (extended-release cabotegravir), the first long-acting injectable option for HIV prevention. The shots, which are administered by a ...

Please provide your email address to receive an email when new articles are posted on . Among nearly 2,500 women, almost 80% chose long-acting, injectable cabotegravir for HIV PrEP. Reasons included ...

Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden administration announced October 21. The news comes just weeks after it was announced ...